Three visionaries for HRT

Anderson GL, Chlebowski RT, Aragaki AK, Kuller LH, Manson JE, et al. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women’s Health Initiative randomised placebo-controlled trial. Lancet Oncology. 2012; 13: 476–486. PubMed: https://pubmed.ncbi.nlm.nih.gov/22401913/

Chlebowski RT, Garnet L, Anderson GL, et al. Long-term influence of estrogen plus progestin and estrogen alone use on Breast cancer incidence: The Women’s Health Initiative Randomised Trials. San Antonio Breast Cancer Symposium. 2019.

Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet. 1997; 350: 1047-1059. PubMed: https://pubmed.ncbi.nlm.nih.gov/10213546/

Shapiro S, Farmer RDT, Seaman H, Stevenson JC, Mueck AO. Does hormone replacement therapy cause breast cancer? An application of causal principles to three studies Part 1. The Collaborative Reanalysis. J Fam Plann Reprod Health Care. 2011; 37: 103-109. PubMed:https://pubmed.ncbi.nlm.nih.gov/21454266/

Manyonda I, Onwude JL. Rapid response to: Use of hormone replacement therapy and risk of breast cancer: nested case-control studies using the QResearch and CPRD databases. BMJ. 2020; 371.

Manyonda I, Talaulikar VS, Pirhadi R, Onwude J. Progestogens are the problem in hormone replacement therapy: Time to reappraise their use. 2019.

Robert Wilson. Feminine Forever. Publisher: WH Allen Publishing. USA. 1966.

Cooper W. No Change. Hutchinson Publishing, 1975.

Gorman T. Hooray to HRT. 2013.